


Clear Cell Epithelial Ovarian Cancer Treatment and Follow-up Pathway Map

Version 2018.06





Target Population

Women presenting with epithelial ovarian cancer

Pathway Map Considerations

- For more information about the optimal organization of gynecologic oncology services in Ontario refer to EBS #4-11
- The staging system used throughout the Ovarian Cancer Treatment Pathway Map is the 2014 FIGO staging system.
- Primary care providers play an important role in the cancer journey and should be informed of relevant tests and consultations.
 Ongoing care with a primary care provider is assumed to be part of the pathway map. For patients who do not have a primary care provider, Health Care Connect, is a government resource that helps patients find a doctor or nurse practitioner.
- Throughout the pathway map, a shared decision-making model should be implemented to enable and encourage patients to play an active role in the management of their care. For more information see Person-Centered Care Guideline and EBS #19-2 Provider-Patient Communication*
- Hyperlinks are used throughout the pathway map to provide information about relevant CCO tools, resources and guidance documents.
- The term 'healthcare provider', used throughout the pathway map, includes primary care providers and specialists, e.g. family doctors, nurse practitioners, gynecologists, midwives and emergency physicians.
- For more information on Multidisciplinary Cancer Conferences visit MCC Tools
- For more information on wait time prioritization, visit: **Surgery**
- Clinical trials should be considered for all phases of the pathway map.
- Psychosocial oncology (PSO) is the interprofessional specialty concerned with understanding and treating the social, practical, psychological, emotional, spiritual and functional needs and quality-of-life impact that cancer has on patients and their families. Psychosocial care should be considered an integral and standardized part of cancer care for patients and their families at all stages of the illness trajectory. For more information, visit EBS #19-3*
- The following should be considered when weighing the treatment options described in this pathway map for patients with potentially life-limiting illness:
 - Palliative care may be of benefit at any stage of the cancer journey, and may enhance other types of care including restorative or rehabilitative care or may become the total focus of care
 - Ongoing discussions regarding goals of care is central to palliative care, and is an important part of the decision-making
 process. Goals of care discussions include the type, extent and goal of a treatment or care plan, where care will be provided,
 which health care providers will provide the care, and the patient's overall approach to care

Pathway Map Legend Shape Guide Colour Guide Intervention **Primary Care** Decision or assessment point **Palliative Care** Patient (disease) characteristics **Pathology** Consultation with specialist **Gynecologic Oncology** Exit pathway **Radiation Oncology** > Off-page reference **Medical Oncology** Patient/Provider interaction R Radiology Referral Gynecology Wait time indicator time point Genetics Line Guide Multidisciplinary Cancer Conference (MCC) Required Possible

Pathway Map Disclaimer

This pathway map is a resource that provides an overview of the treatment that an individual in the Ontario cancer system may receive.

The pathway map is intended to be used for informational purposes only. The pathway map is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. Further, all pathway maps are subject to clinical judgment and actual practice patterns may not follow the proposed steps set out in the pathway map. In the situation where the reader is not a healthcare provider, the reader should always consult a healthcare provider if he/she has any questions regarding the information set out in the pathway map. The information in the pathway map does not create a physician-patient relationship between Cancer Care Ontario (CCO) and the reader.

While care has been taken in the preparation of the information contained in the pathway map, such information is provided on an "as-is" basis, without any representation, warranty, or condition, whether express, or implied, statutory or otherwise, as to the information's quality, accuracy, currency, completeness, or reliability.


CCO and the pathway map's content providers (including the physicians who contributed to the information in the pathway map) shall have no liability, whether direct, indirect, consequential, contingent, special, or incidental, related to or arising from the information in the pathway map or its use thereof, whether based on breach of contract or tort (including negligence), and even if advised of the possibility thereof. Anyone using the information in the pathway map does so at his or her own risk, and by using such information, agrees to indemnify CCO and its content providers from any and all liability, loss, damages, costs and expenses (including legal fees and expenses) arising from such person's use of the information in the pathway map.

This pathway map may not reflect all the available scientific research and is not intended as an exhaustive resource. CCO and its content providers assume no responsibility for omissions or incomplete information in this pathway map. It is possible that other relevant scientific findings may have been reported since completion of this pathway map. This pathway map may be superseded by an updated pathway map on the same topic.

^{*} Note. EBS #19-2 and EBS #19-3 are older than 3 years and are currently listed as 'For Education and Information Purposes'. This means that the recommendations will no longer be maintained but may still be useful for academic or other information purposes.

The pathway map is intended to be used for informational purposes only. The pathway map is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. Further, all pathway maps are subject to clinical judgment and actual practice patterns may not follow the proposed steps set out in the pathway map. In the situation where the reader is not a healthcare provider, the reader should always consult a healthcare provider if he/she has any questions regarding the information in the pathway map does not create a physician-patient relationship between Cancer Care Ontario (CCO) and the reader.

Screen for psychosocial needs, and assessment and management of symptoms. Click here for more information about symptom assessment and management tools




¹ Discussion to be individualized for each patient; however, may include the following: age, fertility preservation, hormone replacement therapy, referral for infertility consultation, etc.

² Pathologists with a specialty or special interest in gynecologic pathology.

³ If appropriate, the option of fertility sparing surgery should be discussed with the patient.

The pathway map is intended to be used for informational purposes only. The pathway map is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. Further, all pathway maps are subject to clinical judgment and actual practice patterns may not follow the proposed steps set out in the pathway map. In the situation where the reader is not a healthcare provider, the reader should always consult a healthcare provider if he/she has any questions regarding the information in the pathway map does not create a physician-patient relationship between Cancer Care Ontario (CCO) and the reader.

Screen for psychosocial needs, and assessment and management of symptoms. Click here for more information about symptom assessment and management tools





¹ Discussion to be individualized for each patient; however, may include the following: age, fertility preservation, hormone replacement therapy, referral for infertility consultation, etc.

² Pathologists with a specialty or special interest in gynecologic pathology

The pathway map is intended to be used for informational purposes only. The pathway map is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. Further, all pathway maps are subject to clinical judgment and actual practice patterns may not follow the proposed steps set out in the pathway map. In the situation where the reader is not a healthcare provider, the reader should always consult a healthcare provider if he/she has any questions regarding the information in the pathway map. The information in the pathway map does not create a physician-patient relationship between Cancer Care Ontario (CCO) and the reader.

Screen for psychosocial needs, and assessment and management of symptoms. Click here for more information about symptom assessment and management tools






⁴ Referral to genetics if patient meets MOH criteria for genetic testing for Lynch syndrome

The pathway map is intended to be used for informational purposes only. The pathway map is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. Further, all pathway maps are subject to clinical judgment and actual practice patterns may not follow the proposed steps set out in the pathway map. In the situation where the reader is not a healthcare provider, the reader should always consult a healthcare provider if he/she has any questions regarding the information in the pathway map. The information in the pathway map does not create a physician-patient relationship between Cancer Care Ontario (CCO) and the reader.

Screen for psychosocial needs, and assessment and management of symptoms. Click here for more information about symptom assessment and management tools



¹ Discussion to be individualized for each patient; however, may include the following: age, fertility preservation, hormone replacement therapy, referral for infertility consultation, etc.

⁴ Referral to genetics if patient meets MOH criteria for genetic testing for Lynch syndrome

⁵To determine the appropriateness for surgery, the following should be taken into consideration: performance status, response to chemotherapy, surgical resectability, and patient comorbidities


⁶ The potential role of radiotherapy should be discussed at the MCC

⁷ When available, clinical trials are to be a priority in this patient population.

For more information about early palliative care for advanced cancer refer to Zimmermann et al., (2014) Early palliative care for patients with advanced cancer. a cluster-randomized controlled trial. Lancet, 383(9930), 1721-30.


The pathway map is intended to be used for informational purposes only. The pathway map is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. Further, all pathway maps are subject to clinical judgment and actual practice patherns may not follow the proposed steps set out in the pathway map. In the situation where the reader is not a healthcare provider, the reader should always consult a healthcare provider if he/she has any questions regarding the information in the pathway map. The information in the pathway map does not create a physician-patient relationship between Cancer Care Ontario (CCO) and the reader.

Screen for psychosocial needs, and assessment and management of symptoms. Click here for more information about symptom assessment and management tools



The pathway map is intended to be used for informational purposes only. The pathway map is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. Further, all pathway maps are subject to clinical judgment and actual practice patterns may not follow the proposed steps set out in the pathway map. In the situation where the reader is not a healthcare provider, the reader should always consult a healthcare provider if he/she has any questions regarding the information in the pathway map does not create a physician-patient relationship between Cancer Care Ontario (CCO) and the reader.

Screen for psychosocial needs, and assessment and management of symptoms. Click here for more information about symptom assessment and management tools



⁴ Referral to genetics if patient meets MOH criteria for genetic testing for Lynch syndrome

⁷ When available, clinical trials are to be a priority in this patient population.

The pathway map is intended to be used for informational purposes only. The pathway map is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. Further, all pathway maps are subject to clinical judgment and actual practice patterns may not follow the proposed steps set out in the pathway map. In the situation where the reader is not a healthcare provider, the reader should always consult a healthcare provider if he/she has any questions regarding the information in the pathway map. The information in the pathway map does not create a physician-patient relationship between Cancer Care Ontario (CCO) and the reader.

End of Life Care ☐ Revisit Advance Care Planning Ensure the patient has determined who will be their Substitute Decision Maker (SDM) Ensure the patient has communicated to the SDM his/her wishes, values and beliefs to help quide that SDM in future decision making □ Discuss and document goals of care with patient and family Assess and address patient and family's information needs and understanding of the disease, address gaps between reality and expectation, foster realistic hope and provide opportunity to explore prognosis and life expectancy, and preparedness for death Introduce patient and family to resources in community (e.g., day hospice programs) **Triggers that** Screen, Assess. Develop a plan of treatment and obtain consent suggest patients **Pathway Map Target** Plan, Manage Determine who the person wants to include in the decision making process (e.g., substitute decision maker if the person is incapable) are nearing the and Follow-Up Population: Develop a plan of treatment related to disease management that takes into account the person's values and mutually determined goals of care last few months Individuals with cancer Obtain consent from the capable person or the substitute decision maker if the person is incapable for an end-of-life plan of treatment that includes: and weeks life - Setting for care approaching end of life, and their - Resuscitation status families. - Having, withholding and or withdrawing treatments (e.g. lab tests, medications, etc.) ECOG/Patient-While this section of the pathway ECOG/PRFS = 4 ☐ Screen for specific end of life psychosocial issues map is focused on the care **End of Life Care** OR Specific examples of psychological needs include: anticipatory grief, past trauma or losses, preparing children (young children, adolescents, young delivered at the end of life, the planning and PPS ≤ 30 adults), guardianship of children, death anxiety palliative care approach begins implementation Declining • Consider referral to available resources and/or specialized services much earlier on in the illness Collaboration and performance trajectory. consultation status/functional Identify patients who could benefit from specialized palliative care services (consultation or transfer) Refer to Screen, Assess & Plan between ability Discuss referral with patients and family within the Psychosocial & specialist-level Gold Standards Palliative Care Pathway Map care teams and ☐ Proactively develop and implement a plan for expected death Framework primary care indicators of high Explore place-of-death preferences and assess whether this is realistic teams mortality risk Explore the potential settings of dying and the resources required (e.g., home, residential hospice, palliative care unit, long term care or nursing home) Anticipate/Plan for pain & symptom management medications and consider a Symptom Response Kit (SRK) for unexpected pain & symptom Preparation and support for family to manage Discuss emergency plans with patient and family (who to call if emergency in the home or long-term-care or retirement home) ☐ Home care planning Connect with Home and Community Care early (not just for last 2-4 weeks) Ensure resources and elements in place Consider a Symptom Response Kit (SRK) with access to pain, dyspnea and delirium medication Identify family members at risk for abnormal/complicated grieving and connect them proactively with bereavement resources

The pathway map is intended to be used for informational purposes only. The pathway map is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. Further, all pathway maps are subject to clinical judgment and actual practice patterns may not follow the proposed steps set out in the pathway map. In the situation where the reader is not a healthcare provider, the reader should always consult a healthcare provider if he/she has any questions regarding the information in the pathway map. The information in the pathway map does not create a physician-patient relationship between Cancer Care Ontario (CCO) and the

